Comparison Chart Celldex Therapeutics, Inc.

Equities

Real-time Estimate Cboe BZX Other stock markets 02:13:06 2024-05-22 pm EDT			5-day change	1st Jan Change
37.86 ^USD	+0.50%		-5.54%	-4.32%

May. 15	Celldex Therapeutics Reports First Patient Dosed in Phase 2 Skin Disorder Study	MT
May. 15	Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis	CI

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes

		Sector	Change	5d. change	1st Jan change	1-year change	5-years change	Capi.	ST	MT	LT
	CELLDEX THERAPEUTICS, INC.	Other Biotechnology & Medical Research	+0.73%	-5.54%	-4.32%	+12.86%	+1,056.86%	2.48B